Entrepreneurial Support Program(Explore Course)
- Principal Investigator
-
The University of Tokyo
Takahiro Nomoto
- Adopted Theme
Development of medicines for vascular-targeted photodynamic therapy
- Subject of Research
- Development of medicines for vascular-targeted photodynamic therapy
- GTIE VC Collective
Advanced Technology Acceleration Corporation (ATAC)
- Overview
-
In this project, we develop and commercialize new medicines for vascular-targeted photodynamic therapy (VPDT). Our technology works by cutting off the oxygen and nutrient supply to tumors through the selective destruction of tumor blood vessels. This process starves the tumor and leads to its shrinkage. With our own photosensitizer created from basic scientific research, we provide better medical results than current methods.
- Business Models（when applying）
We provide medical technology that aims for complete cures in diseases where existing methods fall short. In this project, we conduct our early-stage research and development in Japan to take advantage of the lower R&D costs compared to the US and Europe. From the clinical development stage onward, we plan to target the global market, particularly the United States, for our final exit and potential acquisition by overseas pharmaceutical companies.
- Activity Planning（when applying）
We will establish pre-clinical Proof of Concept for our VPDT formulation to support a final investment decision. This includes building a research and development foundation that allows us to launch a startup and proceed to GLP safety testing, CMC preparation, and IND filing. We also aim to incorporate the company with an appropriate management team that possesses the necessary expertise in R&D management, fundraising, and capital policy planning.